Why did Royalty Pharma raise its 2026 Portfolio Receipts guidance?

The company attributed the raise to strong financial performance and the strength of its diversified portfolio. The new range is $3,400 million to $3,500 million, up from $3,325 million to $3,450 million, and includes expected Royalty Receipts growth of 7% to 10%.

What drove the growth in Royalty Receipts?

Royalty Receipts rose 14% to $768 million, primarily driven by Tremfya, Voranigo, Imdelltra and Evrysdi. Declines from Promacta, due to U.S. generic competition, and Imbruvica partly offset the increase. Evrysdi also benefited from additional royalties acquired in December 2025.

Why did total Portfolio Receipts grow less than Royalty Receipts?

Milestones and other contractual receipts fell to $5 million from $56 million, reflecting a one-time distribution received in the prior-year period. This held Portfolio Receipts growth to 6%, versus 14% for Royalty Receipts.

What is the company's debt and liquidity position?

As of June 30, 2026, Royalty Pharma had cash and cash equivalents of $812 million and total debt with principal value of $9.2 billion. The $380 million term loan was repaid in July 2026, and the company expects 2026 interest paid of $350 million to $360 million, assuming no additional debt financing in 2026.

What new transactions did Royalty Pharma announce?

As of August 4, 2026, the company had announced new transactions of up to $1.7 billion, including potential milestones. In July 2026 it acquired a portion of Neurimmune AG's royalty interest in AstraZeneca's cliramitug, a Phase 3 antibody for TTR amyloidosis with cardiomyopathy, for up to $425 million, including $125 million upfront.

RPRX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed August 5, 2026. Cited figures are marked; the original filing is the authoritative source.

Royalty Pharma plc (Nasdaq: RPRX) reported second quarter 2026 results on August 5, 2026, via a press release furnished as Exhibit 99.1.

Royalty Receipts grew 14% to $768 million^a, driven by Tremfya, Voranigo, Imdelltra and Evrysdi, partly offset by declines from Promacta (U.S. generic competition) and Imbruvica. Portfolio Receipts rose 6% to $773 million, though milestones and other contractual receipts fell to $5 million from $56 million, reflecting a one-time distribution in the prior-year period. Net cash provided by operating activities was $728 million versus $364 million a year earlier, and Adjusted EBITDA (non-GAAP) was $736 million, up 16%.

Management raised full-year 2026 Portfolio Receipts guidance to $3,400 million to $3,500 million^b from $3,325 million to $3,450 million, implying expected Royalty Receipts growth of 7% to 10%. Guidance excludes transactions announced after the release date. Interest paid is expected to be $350 million to $360 million, and the $380 million term loan was repaid in July 2026.

As of June 30, 2026, the company held cash and cash equivalents of $812 million^c and total debt with principal value of $9.2 billion. Capital Deployment was $349 million in the quarter, and the company disclosed new transactions of up to $1.7 billion as of August 4, 2026, including a July 2026 acquisition of a portion of the royalty on AstraZeneca's cliramitug for up to $425 million ($125 million upfront).

02—Key points

Key Highlights

Royalty Receipts up 14% to $768 million in Q2 2026, led by Tremfya, Voranigo, Imdelltra and Evrysdi
Portfolio Receipts up 6% to $773 million; milestones and other contractual receipts fell to $5 million from $56 million
Net cash provided by operating activities of $728 million, versus $364 million in Q2 2025
Adjusted EBITDA (non-GAAP) of $736 million; Portfolio Cash Flow (non-GAAP) of $736 million
Full-year 2026 Portfolio Receipts guidance raised to $3,400 million–$3,500 million from $3,325 million–$3,450 million
Cash of $812 million and total debt principal of $9.2 billion as of June 30, 2026; $380 million term loan repaid in July 2026
New transactions of up to $1.7 billion announced as of August 4, 2026, including the cliramitug royalty acquisition

03—Questions

Frequently Asked Questions

Why did Royalty Pharma raise its 2026 Portfolio Receipts guidance?
The company attributed the raise to strong financial performance and the strength of its diversified portfolio. The new range is $3,400 million to $3,500 million, up from $3,325 million to $3,450 million, and includes expected Royalty Receipts growth of 7% to 10%.
What drove the growth in Royalty Receipts?
Royalty Receipts rose 14% to $768 million, primarily driven by Tremfya, Voranigo, Imdelltra and Evrysdi. Declines from Promacta, due to U.S. generic competition, and Imbruvica partly offset the increase. Evrysdi also benefited from additional royalties acquired in December 2025.
Why did total Portfolio Receipts grow less than Royalty Receipts?
Milestones and other contractual receipts fell to $5 million from $56 million, reflecting a one-time distribution received in the prior-year period. This held Portfolio Receipts growth to 6%, versus 14% for Royalty Receipts.
What is the company's debt and liquidity position?
As of June 30, 2026, Royalty Pharma had cash and cash equivalents of $812 million and total debt with principal value of $9.2 billion. The $380 million term loan was repaid in July 2026, and the company expects 2026 interest paid of $350 million to $360 million, assuming no additional debt financing in 2026.
What new transactions did Royalty Pharma announce?
As of August 4, 2026, the company had announced new transactions of up to $1.7 billion, including potential milestones. In July 2026 it acquired a portion of Neurimmune AG's royalty interest in AstraZeneca's cliramitug, a Phase 3 antibody for TTR amyloidosis with cardiomyopathy, for up to $425 million, including $125 million upfront.

04—Continue

← View all 8-K filings